Optimal Dosing of Breast Cancer Chemotherapy using Robust MPC Based on Linear Matrix Inequalities

In this paper, we consider an application of robust model predictive control to optimal dosing of breast cancer chemotherapy. The model-patient mismatch is handled by computing an ellipsoidal invariant set containing the measured patient’s states at each sampling time. An optimal dose of chemotherapeutic agent is obtained by solving a convex optimization problem subject to linear matrix inequalities. In the case study of simulated patients, the results show that the tumor volume can be reduced to a specified target with up to 30% model-patient mismatch. Moreover, the robust model predictive control algorithm can achieve better treatment results as compared with the nonlinear model predictive control algorithm while the on-line computational time is significantly reduced.

[1]  S. Joe Qin,et al.  A survey of industrial model predictive control technology , 2003 .

[2]  Ali Ghaffari,et al.  Optimal therapeutic protocols in cancer immunotherapy , 2010, Comput. Biol. Medicine.

[3]  S. Namkoong,et al.  Multiparametric flow cytometric analysis in a breast cancer cell line (MCF‐7) , 2002, The journal of obstetrics and gynaecology research.

[4]  Stephen P. Boyd,et al.  Convex Optimization: Convex optimization problems , 2004 .

[5]  S. Sager,et al.  Optimal control for selected cancer chemotherapy ODE models: a view on the potential of optimal schedules and choice of objective function. , 2011, Mathematical biosciences.

[6]  A. Radunskaya,et al.  Mixed Immunotherapy and Chemotherapy of Tumors: Modeling, Applications and Biological Interpretations , 2022 .

[7]  Jos F. Sturm,et al.  A Matlab toolbox for optimization over symmetric cones , 1999 .

[8]  Raj Jena,et al.  Optimal dosing of cancer chemotherapy using model predictive control and moving horizon state/parameter estimation , 2012, Comput. Methods Programs Biomed..

[9]  Kwong-Sak Leung,et al.  A Memetic Algorithm for Multiple-Drug Cancer Chemotherapy Schedule Optimization , 2007, IEEE Transactions on Systems, Man, and Cybernetics, Part B (Cybernetics).

[10]  Julie L. Eiseman,et al.  Antitumor activity, distribution, and metabolism of 13-cis -retinoic acid as a single agent or in combination with tamoxifen in established human MCF-7 xenografts in mice , 1999, Cancer Chemotherapy and Pharmacology.

[11]  S Chareyron,et al.  Mixed immunotherapy and chemotherapy of tumors: feedback design and model updating schemes. , 2009, Journal of theoretical biology.

[12]  S. Kheawhom,et al.  Robust Constrained MPC based on Nominal Performance Cost with Applications in Chemical Processes , 2012 .

[13]  Johan Löfberg,et al.  Automatic robust convex programming , 2012, Optim. Methods Softw..

[14]  Roland Tóth.  LPV Modeling of Physical Systems , 2010 .

[15]  S. Lakshminarayanan,et al.  Global sensitivity analysis and model-based reactive scheduling of targeted cancer immunotherapy , 2010, Biosyst..

[16]  S. Robinson,et al.  Metabolites, pharmacodynamics, and pharmacokinetics of tamoxifen in rats and mice compared to the breast cancer patient. , 1991, Drug metabolism and disposition: the biological fate of chemicals.

[17]  Efstratios N. Pistikopoulos,et al.  Optimal Delivery of Chemotherapeutic Agents in Cancer , 2006 .

[18]  Robert S Parker,et al.  Nonlinear model predictive control for dosing daily anticancer agents using a novel saturating-rate cell-cycle model , 2008, Comput. Biol. Medicine.

[19]  G Y Locker,et al.  Hormonal therapy of breast cancer. , 1998, Cancer treatment reviews.

[20]  Jay H. Lee,et al.  Model predictive control: Review of the three decades of development , 2011 .

[21]  Benedetto Piccoli,et al.  Determination of the optimal therapeutic protocols in cancer immunotherapy. , 2007, Mathematical biosciences.